Table 1 Clinicalf data of patients
From: Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients
Patient | Diagnosis/rheumatoid factor | Sex, age (years) | Time of diagnosis | Duration of arthritis | DMARD | Corticosteroids | EULAR response criteria | TNF staining before treatmenta |
|---|---|---|---|---|---|---|---|---|
1 | RA, positive | Female, 55 | 18 years | NA | Methotrexate 7.5 mg/week | Prednisolone 5 mg/day | None | 0 |
2 | RA, positive | Female, 52 | 6 years | 2 weeks | Methotrexate 17.5 mg/week | Prednisolone 5 mg/day | Moderate | 0 |
3 | RA, positive | Female, 58 | 2 years | 6 months | Methotrexate 7.5 mg/week | Prednisolone 7.5 mg/day | Moderate | 1 |
4 | RA, negative | Female, 57 | 4 years | 2 weeks | Methotrexate 10 mg/week | None | None | 0 |
5 | RA, positive | Male, 56 | 9 years | 1 month | Methotrexate 7.5 mg/week | Prednisolone 5 mg/day | Good | 1 |
6 | RA, negative | Female, 69 | 1 year | 1 year | Methotrexate 15 mg/week | Prednisolon 5 mg/day | Good | 1 |
7 | RA, positive | Female, 66 | 14 years | 1 week | Methotrexate 10 mg/week | None | Moderate | 0 |
8 | RA, positive | Female, 66 | 10 years | 3 weeks | Methotrexate 12.5 mg/week | None | Moderate | 0 |
9 | RA, positive | Male, 25 | 7 months | 3 days | Methotrexate 17.5 mg/day | Prednisolon 20-7.5 mg/day | Moderate | 0 |
10 | RA, positive | Female, 35 | 26 years | 1 year | Methotrexate 17.5 mg/day | Prednisolon 7.5 mg/day | Good | 1 |